false
0001725430
0001725430
2024-05-08
2024-05-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): May 8, 2024
INTELLIGENT
BIO SOLUTIONS INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-39825 |
|
82-1512711 |
(State
of
Incorporation) |
|
(Commission
File Number) |
|
(IRS
employer
identification no.) |
142
West, 57th Street, 11th Floor
New
York, NY 10019
(Address
of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: (646) 828-8258
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.01 par value |
|
INBS |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 Results of Operations and Financial Condition.
On
May 8, 2024, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing
financial results for the fiscal quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall
not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
May 8, 2024 |
|
|
|
INTELLIGENT
BIO SOLUTIONS INC. |
|
|
|
|
By:
|
/s/
Spiro Sakiris |
|
Name:
|
Spiro
Sakiris |
|
Title: |
Chief
Financial Officer |
Exhibit
99.1
Intelligent
Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and
Nine-Month
Financial Results and Operational Highlights
Year-over-year
revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024
Cash
and cash equivalents as of March 31, 2024, was $9.40 million
Commenced
FDA 510(k) clinical studies plan with Cliantha Research and remains on track for planned submission by the end of 2024 and planned entry
into the US in 2025
Secured
26 new customer accounts throughout the quarter, representing a combined headcount of approximately 16,779 employees
NEW
YORK, May 8, 2024 —Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”),
a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for
the fiscal third quarter and nine months ended March 31, 2024, and provided a business update.
“We
are pleased to report our third consecutive quarter of strong revenue growth, which was driven by the acquisition of 26 new accounts
and a steadily increasing install base. We have made significant progress on our FDA 510(k) roadmap, entering the critical phase of clinical
validation with Cliantha Research, and are on track to complete our 510(k) submission, expected by the end of 2024,” said Harry
Simeonidis, President and CEO at INBS. “With a solid financial foundation, we are well-prepared to execute on our deliverables,
which include expanding into new regions and customer segments, advancing our FDA pathway, and continuing to lead innovation in our field.”
“We
are pleased to report that the Company continues its upward revenue trend,” said Spiro Sakiris, CFO at INBS. “Sales growth
of 80% year-over-year and a capital injection of approximately $10.76 million have greatly improved our financial position and will provide
the resources to accelerate our expansion. Our dedicated team has done an amazing job executing our business plan, and it is this dedication
that will drive us to the next level.”
Financial
Results for the Fiscal 2024 Third Quarter:
| ● | Total
cash and cash equivalents on hand as of March 31, 2024, was $9.40 million, an increase from
$1.1 million on December 31, 2023. |
| ● | Shareholders
equity as of March 31, 2024, was $11 million. |
| ● | Total
revenues for the fiscal third quarter were $0.82 million, an increase of 80% compared to
the same period the year prior. |
| ● | Total
revenue for the nine months ended March 2024 was $2.38 million, an increase of 193% compared
to the same period the year prior. |
| ● | Net
loss for the fiscal third quarter was $2.98 million which included non-cash depreciation
and amortization and share based expenses of $0.54 million. |
Revenue
from sales of goods increased by $366,742 from $457,058 to $823,800 for the quarter ended March 31, 2024, compared to the same period
in 2023, representing an 80% increase. Revenue from sales of goods increased by $1.57 million from $813,737 to $2.38 million for the
nine months ended March 31, 2024, compared to the same period in 2023, representing a 193% increase. Increases in revenue are due to
the organic growth of the business and expansion into new regions and customer segments following the acquisition of Intelligent Fingerprinting
Ltd (“IFP”) in October 2022.
Net
loss attributable to INBS decreased by $600,287 from $7.97 million to $7.37 million for the nine months ended March 31, 2024, compared
to the same period the year prior. This decrease is primarily driven by goodwill impairment charges of $4.10 million and combined results
of operations after the acquisition of IFP, offset by a recognition of fair value gain on revaluation of convertible notes and holdback
Series C Preferred Stock of $2.06 million during the same period in 2023. During the quarter, the Company raised approximately $10.76
million after deducting closing costs, placement agent fees, and other estimated expenses payable by the Company via warrant inducement
transaction and a private placement of the Company’s securities. The Company ended the quarter with cash and cash equivalents of
approximately $9.40 million.
Fiscal
Third Quarter & Recent Operational Highlights:
| ● | On
February 28, 2024, the Company announced its partnership with Cliantha Research to conduct
the pharmacokinetic (PK) study as part of its FDA 510(k) clinical studies plan. The Company
remains on track for its planned entry into the US market in 2025. |
| ● | 26
new accounts secured throughout the quarter, representing a combined headcount of approximately
16,779 employees. |
| ● | The
Company was granted a new European patent with unitary effect for its DSR-Plus Cartridge
Reader, bringing the patent into effect in 17 European countries. |
About
Intelligent Bio Solutions Inc.
Intelligent
Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company
believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis,
which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens
for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection
in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally,
the Company’s biosensor platform has the potential to test for various indications, ranging from immunological conditions to communicable
diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics
firms, drug treatment organizations, and coroners.
For
more information, visit: http://www.ibs.inc/
Forward-Looking
Statements:
Some
of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties.
Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully
develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure
regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or
implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology,
including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,”
“intends,” “potential,” “may,” “could,” “might,” “will,” “should,”
“approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent
Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this
release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained
in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company
Contact:
Intelligent
Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor
& Media Contact:
Valter
Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
(Financial
tables follow)
Intelligent
Bio Solutions Inc.
Condensed
Consolidated Balance Sheets
(Amounts
in US$)
| |
As of March 31, | | |
As of June 30, | |
| |
2024 | | |
2023 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 9,397,523 | | |
$ | 1,537,244 | |
Accounts receivable, net | |
| 431,646 | | |
| 293,861 | |
Inventories, net | |
| 877,905 | | |
| 979,907 | |
Research and development tax incentive receivable | |
| 332,471 | | |
| 498,758 | |
Other current assets | |
| 481,046 | | |
| 552,791 | |
Total current assets | |
| 11,520,591 | | |
| 3,862,561 | |
Property and equipment, net | |
| 559,520 | | |
| 690,175 | |
Operating lease right-of-use assets | |
| 365,512 | | |
| 546,475 | |
Intangibles, net | |
| 4,593,330 | | |
| 5,255,401 | |
Total assets | |
$ | 17,038,953 | | |
$ | 10,354,612 | |
| |
| | | |
| | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 2,128,747 | | |
$ | 2,610,028 | |
Current portion of operating lease liabilities | |
| 260,377 | | |
| 223,447 | |
Current portion of deferred grant income | |
| 2,288,660 | | |
| 2,338,057 | |
Current employee benefit liabilities | |
| 660,010 | | |
| 358,942 | |
Current portion of notes payable | |
| 368,513 | | |
| 353,211 | |
Total current liabilities | |
| 5,706,307 | | |
| 5,883,685 | |
Employee benefit liabilities, less current portion | |
| 30,286 | | |
| 24,902 | |
Operating lease liabilities, less current portion | |
| 154,162 | | |
| 356,165 | |
Notes payable, less current portion | |
| 150,426 | | |
| 402,862 | |
Total liabilities | |
| 6,041,181 | | |
| 6,667,614 | |
Commitments and contingencies | |
| - | | |
| - | |
| |
| | | |
| | |
Shareholders’ equity | |
| | | |
| | |
Common stock, $0.01 par value, 100,000,000 shares authorized, 2,913,799 and 194,200 shares issued and outstanding at March 31, 2024 and June 30, 2023, respectively* | |
| 29,135 | | |
| 1,942 | |
Treasury stock, at cost, 116 shares as of March 31, 2024 and June 30, 2023, respectively* | |
| (1 | ) | |
| (1 | ) |
Additional paid-in capital | |
| 60,946,174 | | |
| 46,180,112 | |
Accumulated deficit | |
| (49,180,085 | ) | |
| (41,807,573 | ) |
Accumulated other comprehensive loss | |
| (662,405 | ) | |
| (575,496 | ) |
Total consolidated Intelligent Bio Solutions Inc. equity | |
| 11,132,818 | | |
| 3,798,984 | |
Non-controlling interest | |
| (135,046 | ) | |
| (111,986 | ) |
Total shareholders’ equity | |
| 10,997,772 | | |
| 3,686,998 | |
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | |
$ | 17,038,953 | | |
$ | 10,354,612 | |
* |
Common
stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse
stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed
consolidated financial statement unless otherwise stated. |
Intelligent
Bio Solutions Inc.
Condensed
Consolidated Statements of Operations and Other Comprehensive Loss*
(Unaudited)
(Amounts
in US$)
| |
Three Months ended March 31, | | |
Nine Months ended March 31, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Revenue | |
$ | 823,800 | | |
$ | 457,058 | | |
$ | 2,383,957 | | |
$ | 813,737 | |
Cost of revenue (exclusive of amortization shown separately below) | |
| (645,311 | ) | |
| (424,009 | ) | |
| (1,773,889 | ) | |
| (536,644 | ) |
Gross profit | |
| 178,489 | | |
| 33,049 | | |
| 610,068 | | |
| 277,093 | |
| |
| | | |
| | | |
| | | |
| | |
Other income: | |
| | | |
| | | |
| | | |
| | |
Government support income | |
| 83,842 | | |
| 117,680 | | |
| 346,917 | | |
| 698,625 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Selling, general and administrative expenses | |
| (2,425,830 | ) | |
| (1,898,754 | ) | |
| (6,587,934 | ) | |
| (5,594,461 | ) |
Development and regulatory approval expenses | |
| (471,313 | ) | |
| (299,898 | ) | |
| (923,712 | ) | |
| (380,363 | ) |
Depreciation and amortization | |
| (318,923 | ) | |
| (398,986 | ) | |
| (916,796 | ) | |
| (797,142 | ) |
Goodwill impairment | |
| - | | |
| (4,096,490 | ) | |
| - | | |
| (4,096,490 | ) |
Total operating expenses | |
| (3,216,066 | ) | |
| (6,694,128 | ) | |
| (8,428,442 | ) | |
| (10,868,456 | ) |
Loss from operations | |
| (2,953,735 | ) | |
| (6,543,399 | ) | |
| (7,471,457 | ) | |
| (9,892,738 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense), net: | |
| | | |
| | | |
| | | |
| | |
Interest expense | |
| (42,674 | ) | |
| (86,125 | ) | |
| (112,590 | ) | |
| (163,957 | ) |
Realized foreign exchange income/(loss) | |
| (996 | ) | |
| 7,212 | | |
| (1,551 | ) | |
| (8,936 | ) |
Fair value gain on revaluation of financial instrument | |
| - | | |
| 269,787 | | |
| 175,738 | | |
| 2,062,878 | |
Interest income | |
| 10,640 | | |
| 508 | | |
| 14,288 | | |
| 9,587 | |
Total other income (expense), net | |
| (33,030 | ) | |
| 191,382 | | |
| 75,885 | | |
| 1,899,572 | |
Net loss | |
| (2,986,765 | ) | |
| (6,352,017 | ) | |
| (7,395,572 | ) | |
| (7,993,166 | ) |
Net loss attributable to non-controlling interest | |
| (9,098 | ) | |
| (8,111 | ) | |
| (23,060 | ) | |
| (20,367 | ) |
Net loss attributable to Intelligent Bio Solutions Inc. | |
$ | (2,977,667 | ) | |
$ | (6,343,906 | ) | |
$ | (7,372,512 | ) | |
$ | (7,972,799 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other comprehensive income/(loss), net of tax: | |
| | | |
| | | |
| | | |
| | |
Foreign currency translation gain/ (loss) | |
| (144,026 | ) | |
| (77,787 | ) | |
| (86,909 | ) | |
| 148,251 | |
Total other comprehensive income/(loss) | |
| (144,026 | ) | |
| (77,787 | ) | |
| (86,909 | ) | |
| 148,251 | |
Comprehensive loss | |
| (3,130,791 | ) | |
| (6,429,804 | ) | |
| (7,482,481 | ) | |
| (7,844,915 | ) |
Comprehensive loss attributable to non-controlling interest | |
| (9,098 | ) | |
| (8,111 | ) | |
| (23,060 | ) | |
| (20,367 | ) |
Comprehensive loss attributable to Intelligent Bio Solutions Inc. | |
| (3,121,693 | ) | |
| (6,421,693 | ) | |
| (7,459,421 | ) | |
| (7,824,548 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share, basic and diluted* | |
$ | (1.43 | ) | |
$ | (68.67 | ) | |
$ | (6.64 | ) | |
$ | (104.04 | ) |
Weighted average shares outstanding, basic and diluted* | |
| 2,079,864 | | |
| 92,389 | | |
| 1,110,089 | | |
| 76,629 | |
* |
Common
stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse
stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed
consolidated financial statement unless otherwise stated. |
v3.24.1.u1
Cover
|
May 08, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
May 08, 2024
|
Entity File Number |
001-39825
|
Entity Registrant Name |
INTELLIGENT
BIO SOLUTIONS INC.
|
Entity Central Index Key |
0001725430
|
Entity Tax Identification Number |
82-1512711
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
142
West, 57th Street
|
Entity Address, Address Line Two |
11th Floor
|
Entity Address, City or Town |
New
York
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10019
|
City Area Code |
(646)
|
Local Phone Number |
828-8258
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.01 par value
|
Trading Symbol |
INBS
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Intelligent Bio Solutions (NASDAQ:INBS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Intelligent Bio Solutions (NASDAQ:INBS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024